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Abstract
Background: Aboriginal Australians are at high risk of cardiovascular, metabolic and renal diseases, resulting in a
marked reduction in life expectancy when compared to the rest of the Australian population. This is partly due to
recognized environmental and lifestyle risk factors, but a contribution of genetic susceptibility is also likely.
Methods: Using results from a comprehensive survey of one community (N = 1350 examined individuals), we have
tested for familial aggregation of plasma glucose, arterial blood pressure, albuminuria (measured as urinary albumin
to creatinine ratio, UACR) and estimated glomerular filtration rate (eGFR), and quantified the contribution of
variation at four candidate genes (ACE; TP53; ENOS3; MTHFR).
Results: In the subsample of 357 individuals with complete genotype and phenotype data we showed that both
UACR (h2 = 64%) and blood pressure (sBP h2 = 29%, dBP, h2 = 11%) were significantly heritable. The ACE insertion-
deletion (P = 0.0009) and TP53 codon72 polymorphisms (P = 0.003) together contributed approximately 15% of the
total heritability of UACR, with an effect of ACE genotype on BP also clearly evident.
Conclusions: While the effects of the ACE insertion-deletion on risk of renal disease (especially in the setting of
diabetes) are well recognized, this is only the second study to implicate p53 genotype as a risk factor for
albuminuria - the other being an earlier study we performed in a different Aboriginal community (McDonald et al.,
J Am Soc Nephrol 13: 677-83, 2002). We conclude that there are significant genetic contributions to the high
prevalence of chronic diseases observed in this population.
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Background
Chronic diseases such as diabetes mellitus, hypertension,
ischaemic heart disease, and chronic renal failure are far
more common among Aboriginal Australians than they
are in Australians of European descent [2–5]. This is espe-
cially true of Aboriginal communities in the “Top End”,
the tropical northern part of the Northern Territory. In
one community, we have demonstrated that these findings
can be explained, at least in part, by the presence of a
number of environmental and behavioural risk factors for
these diseases. Notably, high rates of childhood Group A
streptococcal infection and post-streptococcal glomerulo-
nephritis (up to 28% of one sample under the age of 30
years [6]) were associated with later development of mi-
cro- and macro albuminuria [7, 8]. Obesity, alcohol and
tobacco overuse were also commonly present.
However, we were also intrigued by the fact that end
stage renal disease and albuminuria seemed to aggregate
within particular families in these communities [9], an
observation that might reflect segregation of disease
genes. A number of risk loci have been characterised in
* Correspondence:
9Centre for Chronic Disease, The University of Queensland School of
Medicine, Brisbane, Australia
10Centre for Chronic Disease, Central Clinical School, Royal Brisbane Hospital,
Queensland 4029, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Duffy et al. BMC Nephrology  (2016) 17:183 
DOI 10.1186/s12882-016-0396-2
other ethnic groups: strikingly, the five-fold difference in
incidence of renal diseases between African and European
descended populations is largely due to two coding
variants in the APOL1 gene [10–13]. Using data from
another Aboriginal community we have previously shown
that variants in two other much studied genes, the ACE
insertion-deletion (indel) and TP53*R72P polymorphisms,
are associated with albuminuria and hypertension [1].
ACE encodes angiotensin I converting enzyme, and TP53,
the key tumor suppressor protein p53. The latter is in-
volved in regulating responses to DNA damage, whether
repair or programmed cell death.
We have a particular interest in albuminuria, as mea-
sured by the urinary albumin to creatinine ratio (UACR),
as it is easily measured in the field, and is a good predictor
not just of subsequent development of end stage renal
disease, but also of cardiovascular disease morbidity and
mortality in both diabetics and nondiabetics [4, 5, 14–17].
In the present paper, we quantify the effects of these
ACE and TP53 gene variants in a much larger Aboriginal
Australian sample. Family based analysis is used to com-
pare these effects to those of unmeasured genetic risk
factors acting in this population on UACR, arterial blood
pressure, and plasma glucose.
Methods
Study population
As described elsewhere [2, 4–8], a number of surveys
(interviews and clinical examinations) and an interven-
tion program focusing on renal and cardiovascular
diseases have been carried out in a remote Aboriginal
Australian community living on two islands situated off
the coast of the Northern Territory, north of Darwin.
All participants completed a questionnaire recording
basic demographic information, family relationships, and
medical history. Height, weight and hip and waist
circumferences were recorded. BP was measured by a
single observer using a mercury sphygmomanometer.
Urine and blood were collected for routine biochemical
screening. In a subset of individuals with elevated spot
plasma glucose levels, a 2 h oral glucose tolerance test
was performed. The protocol was approved by the insti-
tutional ethics committee and written informed consent
was obtained from all participants.
Laboratory methods
Urinary albumin and creatinine levels in a spot urine
collection were used to calculate the albumin:creatinine
ratio (UACR), a measurement known to strongly correl-
ate with 24 h urinary albumin excretion. Repeat UACR
measurements were available for only 63 out of 357 indi-
viduals, with a test-retest correlation for log transformed
UACR of 0.97. We estimated eGFR from serum creatin-
ine level using the MDRD Study equation. Whole blood
(4 ml) for DNA analysis was collected into EDTA tubes,
stored at 4 °C until DNA extraction. DNA specimens
were available for 401 subjects. Genotyping was carried
out at 6 polymorphisms in four candidate genes: NOS3
(endothelial nitric oxide synthase; rs2070744, rs1799983,
i4 VNTR), TP53 (rs1042522), MTHFR (methylenetetra
hydrofolate reductase; rs1801133) and ACE (rs4646994)
as previously described [1]. These variants were selected
because of previously reported associations with diabetes
and diabetic nephropathy, or cardiovascular disease (eg
[18–22]), and all were polymorphic in the present popu-
lation (Additional file 1: Table S1).
Statistical methods
Standard statistical analyses were carried out using the R
statistical package [23]. The mgcv [24] and SemiPar pack-
ages [25] were used to investigate nonlinear covariate
effects in penalized spline mixed models (with family-
specific intercepts). The family based variance compo-
nents analyses were carried out using the Sib-pair pro-
gram [26], MENDEL 5.7 [27] and WOMBAT [28].
Urinary albumin to creatinine ratio was log transformed
for subsequent analyses (logACR). Since 162 individuals
had a 2 h OGGT plasma glucose measurement, but 197 a
fasting plasma glucose, we have analysed the latter, using a
log transformation. Familial aggregation of quantitative
traits such as logACR and systolic (sBP) and diastolic (dBP)
blood pressure were carried out using a mixed effects
model (variance components model). In this analysis we re-
late the degree of genetic relationship between individuals
to their similarity in phenotypes. The random effects were
assumed to be multivariate normally distributed, and this
was tested by evaluation of model residuals. We utilized the
usual biometrical decomposition [29] of the variance into
components due to additive genetic random effects (corre-
lated among family members) and residual environmental
effects. The heritability is a commonly quoted summary
statistic from this type of analysis, and is the proportion of
the phenotypic variance of the trait in this population due
to genetic effects. Since we have not modeled household ef-
fects, it is not possible to disentangle the effects of house-
hold and familial environment from genetic effects, and
this should be borne in mind when examining the heritabil-
ity estimates. Fixed effects of age, weight, height, sex and
measured genotype were included in the genetic models.
Results
Clinical data are available for a total of 1350 individuals
from the community, more than 80% of community
members of 5 years of age and over. A subsample of 401
individuals were genotyped, chosen on the basis of their
ranges of urine ACR being representative of that of the
whole community. Pedigrees were successfully con-
structed for 357 of these individuals. There were a total
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of 771 pedigree members (including unphenotyped
“connecting” individuals), with a mean pedigree size of 5.7
individuals (range 3-43), and the deepest pedigree spanned
5 generations. Slightly more males than females were
examined (184 M, 173 F), and ages ranged from 18 to 76
years (see Table 1).
The subsample for the genetic analyses did not differ
significantly from the complete sample in terms of sex
ratio, rates of diabetes, blood pressure or UACR. For
example, 40% of the complete sample aged 40-49 years
were macroalbuminuric (UACR > 33 g/mol) versus 39%
of the familial subsample. This rate can be compared to
the overall albuminuria rate of 5% in the 1.8 million
individuals (mean age 48) from 26 general population
samples described by Nitsch and coworkers [17].
There were strong correlations between the various
different traits (Table 2, Figs. 1, 2 and 3). Unsurprisingly,
both logACR and BP were correlated with age. There
were significant effects of genotype at the ACE indel and
TP53 codon72 polymorphisms on multiple clinically
relevant phenotypes (Additional file 1: Table S2). Micro-
albuminuria (defined as 3.4-33 g/mol) was increased in
ACE D/I carriers compared to I/I carriers (RR = 1.4, and
see Fig. 1), and macroalbuminuria (>33 g/mol) even
further so (RR = 2.2), with 47.5% of D/I carriers macroal-
buminuric, but only 21% of the I/I genotype (P = 0.001).
The effects of ACE genotype on UACR were most
obvious after the age of 30 years (see Fig. 2). The D/I
carriers also had higher systolic (130.4 versus 119.2
mm Hg) and diastolic blood pressures (83.3 versus
70.7 mm Hg) than I/I carriers (Fig. 3; Additional file 1:
Figure S3 and S4), and were four times more likely to
be diabetic (22% versus 5%, and see Fig. 4).
Estimated glomerular filtration rate (eGFR, available
for 335 individuals) was nonlinearly related to logACR,
as well as to weight. It did not show any significant rela-
tionship to ACE or TP53 genotype.
The multivariate genetic variance components analysis
of logACR and BP using MENDEL found that the
correlation between these traits was almost completely
genetic in nature, with little evidence of a unique envir-
onmental (ie intraindividual nongenetic) correlation
(Table 3). The heritability of logACR was 64%, while that
of sBP 24% and dBP only 11%. The multivariate adjusted
effects of ACE genotype (D/I versus I/I) were 6.8 mm
Hg of systolic blood pressure, 8.2 mm Hg of diastolic
blood pressure, and a 2.7-fold increase of UACR (see
Table 4). The effect of the TP53*P72 allele on UACR
was approximately half that of the ACE*D allele: 1.6-fold.
We estimate that approximately 9% of the genetic vari-
ance of logACR is due to ACE, and 5% due to TP53. In
contrast to this, variance components analyses of both
eGFR and serum creatinine levels estimated the herita-
bilities of those traits as not significantly different from
zero.
Discussion
We have now reported a number of studies involving this
Australian Aboriginal community [2, 4–10], documenting
much higher rates of diabetes mellitus, arterial hyperten-
sion, albuminuria and renal disease than are seen in the
general Australian population. In the current work, we
confirm the clinical impression that both albuminuria and
renal insufficiency seems to aggregate within particular
families from this community. Because of the correlation
between our measure of albuminuria (logACR) and blood
pressure, we have carried out multivariate genetic ana-
lyses. These found that logACR was strongly heritable,
while BP less so. The correlation between logACR and BP
was found to be largely genetic in nature.
We further showed that approximately 14% of the gen-
etic variances of logACR and of BP were explained by
polymorphisms at two loci, ACE and TP53. A number of
studies have implicated the ACE insertion/deletion poly-
morphism in risk of diabetic nephropathy. Mooyart and
coworkers’ [30] meta-analysis found 42 studies of ACE,
giving an overall odds ratio for diabetic nephropathy of
1.24 (95% CI 1.12–1.37), for the deletion (D allele), but
Table 1 Descriptive statistics for key phenotypes in individuals with measured UACR
Variable All (N = 357) Males (N = 184) Female (N = 173)
Median Age (range) 34.6 (18.0–76.4) 32.5 (18.0–73.2) 36.5 (18.0–76.4)
Geometric mean UACR (range) 5.3 (0.1–605.8) 6.8 (0.2–605.8) 4.3 (0.1–466.7)
Percentage UACR > 33 g/mol 25.5% 22.8% 28.3%
Median BMI (range) 22.7 (14.2–43.5) 22.1 (14.2–39.1) 23.1 (14.6–43.5)
Median serum creatinine 81.0 (69–589) 91 (63–589) 69 (63–238)
Percentage smokers 26.3% 21.3% 31.7%
Median fasting glucose (range) N = 197 4.7 (3.2–18.1) 4.6 (3.2–17) 4.8 (3.6–18.1)
Percentage fasting glucose > 5.5 22.8% 15.9% 31.1%
Median systolic BP (range) N = 347 120.0 (84–170) 124 (84–170) 114 (89–170)
Median diastolic BP (range) 72 (39–130) 76 (42–130) 70 (39–112)
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comment that the effects are more marked in Asian than
European populations. Their point estimates agree well
with those from the large Diabetes Control and Complica-
tions Trial (DCCT) [31], where the I/I genotype hazard
ratio was 0.7 for microalbuminuria and 0.6 for severe
nephropathy. The effect sizes in the present study are
roughly comparable to the latter (we observed 0.71 and
0.45). Most studies have not found a relationship between
ACE genotype and essential hypertension. For example, in
a meta-analysis of 46 studies, Staessen and coworkers [32]
report that although the ACE D allele clearly increased
risk of coronary heart disease and stroke, the effects on
blood pressure were not significant. In the present study,
the D allele was significantly associated with increased
blood pressure, which may reflect the high rates of renal
disease in this community.
It is interesting to examine the frequency of the ACE
indel across comparable populations to that in the
current study (Table 5). Firstly, the frequency of the
deleterious D allele in our sample is similar to that
reported from other Australian Aboriginal samples. Sec-
ondly, it is less common than in most other world
populations, with a suggestion of an African-European-
Asian-Australian cline.
Table 2 Pearson correlations between key phenotypes and covariables (Pairwise N = 327-357)
Sex Age Ht Wt BMI Cr eGFR ACR dBP sBP
Sex 1.00
Age -0.12 1.00
Height 0.70 -0.01 1.00
Weight 0.21 0.15 0.38 1.00
BMI -0.09 0.17 -0.03 0.91 1.00
Creatinine 0.32 0.14 0.26 0.31 0.21 1.00
eGFR -0.27 -0.38 -0.10 0.45 0.53 -0.47 1.00
logACR -0.11 0.45 -0.01 0.29 0.30 0.19 -0.04 1.00
dBP 0.19 0.32 0.25 0.43 0.35 0.32 -0.07 0.42 1.00
sBP 0.25 0.36 0.24 0.33 0.25 0.27 -0.14 0.33 0.61 1.00
Bolding denotes a correlation that is statistically significantly different from zero (P < 0.05)
Fig. 1 Urinary albumin:creatinine ratio versus ACE insertion-deletion genotype in a sample of Aboriginal Australians. Lines at UACR of 3.4 and 30
g/mol represent suggested diagnostic thresholds for micro- and macroalbuminuria. The notches represent 95 % confidence intervals around the
median of each group
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The codon72 TP53 polymorphism has not been com-
monly studied as a risk factor for renal disease. TP53 is
known to be important in acute renal injury via its role
in regulation of apoptosis and cell survival, and inhib-
ition of TP53 expression by siRNA reduces the acute
kidney injury following administration of aristolochic
acid or renal ischemia-reperfusion in animal models,
although longer term p53 inhibition may promote renal
fibrosis in some species [33, 34]. The Arg72 p53 protein
is more pro-apoptotic and tumour suppressive than the
Pro72 version [35–37], and in the Hupki humanised
mouse model increases rates of obesity and diabetes
when fed a high fat diet [38]. In keeping with the latter,
Burgdorf and coworkers’ metaanalysis of diabetes did
find the R72 allele to increase risk of Type 2 diabetes by
6% [39], though there are no data for diabetic nephropa-
thy per se. A relationship with BP, has also been reported
[40], but we do not confirm this. There are large differ-
ences in frequency between continental populations,
with the ancestral P72 allele common in Africa, and the
R72 allele common in European and Asian populations
(Table 5). In our study, frequency of the R72 allele was
intermediate between Africa and Europe.
In view of the forgoing, this polymorphism is a plaus-
ible candidate, and the association found in our earlier
study with UACR [1] is replicated here in a second
Aboriginal community. That the P72 allele is the risk
allele seems counterintuitive, but this may reflect the
long term versus short term effect. Because the effect of
the R72 allele on human diabetes risk is modest, it is not
surprising that we did not detect any association in the
present study with plasma glucose levels. Exploration of
renal pathology in the humanized R72 prediabetic
mouse model [38] may be of relevance.
For both the ACE and TP53 variants, we should worry
that the risk allele is actually a marker for European admix-
ture or ancestry. One example of such ethnic confounding
was for diabetes risk in Pima indigenous Americans [41].
Unfortunately, we did not have enough genotyped parent-
offspring pairs to carry out a transmission-disequilibrium
test (TDT) to definitively exclude this possibility, but point
estimates from the TDT (not shown) matched that
estimated by the variance components analysis. The ob-
served direction of association is also inconsistent with this
type of confounding, in that given the high prevalence of
disease in the indigenous community, then European
admixture should be protective.
Because we have not used an intrinsically informative
design (such as an adoption or twin study), we cannot
unequivocally differentiate between effects of other
genes and unmeasured shared environmental factors as
cause of the observed familial aggregation. One likely fa-
milial factor would be infection with, for example, group
A streptococci. We did examine other factors such as
Fig. 2 Effect of ACE insertion-deletion genotype on cross-sectional relationship between age and UACR. Upper curve is D/I genotype group; lower,
the I/I genotype group; the dotted line is the overall curve (Flattening of D/I curve after the age of 40 may reflect selective mortality, but there
may be other cohort effects acting)
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birth weight (available for a subset of 110 individuals), but
these did not aggregate strongly enough within families to
act as a confounder [42, 43]. This means we also cannot
address whether particular environmental exposures are
exacerbating the effects of the candidate gene effects that
we have demonstrated, given that the genotypic effect
sizes are larger than those seen in other populations.
We found logACR to be a useful choice in comparison
to other measures of renal function in terms of the
linearity of its relationship with covariates such as age,
and found it to be more heritable than covariate-
adjusted serum creatinine level or glomerular filtration
rate. In the present analysis we have used only cross-
sectional (baseline) data. In previous longitudinal studies
in this community, we have shown that logACR is an
excellent predictor of change in GFR over time [4].
Aside from this, a number of mortality studies have now
shown that albuminuria is a risk predictor independent
of glomerular filtration rate [44]. Microalbuminuria oc-
curs both in the context of systemic vascular endothelial
dysfunction and in podocyte specific disorders, such as
nephrotic syndrome, and so may represent either a com-
mon marker or a common pathway for different patho-
physiological processes [45].
We have previously presented data showing how
UACR increases in this population with age, flattening
off by age 60 years (see Fig. 1 from Reference [14]). Fig. 2
in the present paper shows that the same shape relation-
ship occurs for each ACE indel genotype, but that the I/D
group rise faster, especially after the age of 30 years, but
flattens off by age 45. This may represent effects of differ-
ential mortality or cohort effects – we have reported else-
where that age-specific mortality rates may be improving
in this community with time [46].
Fig. 3 Effect of ACE insertion-deletion genotype on cross-sectional relationship between age and diastolic blood pressure. Upper curve is
D/I genotype group; lower, the I/I genotype group; the dotted line is the overall curve
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Several studies of the genetics of logACR have been pub-
lished that we can compare our results to. These studies
have concentrated on families of containing diabetic pro-
bands, but a common finding is that the heritability of
logACR is the same in diabetic and nondiabetic family
members. Fogarty et al. [47] performed a segregation ana-
lysis of UACR in 1269 individuals (630 diabetics) from 96
families, and concluded that there was strong familial
aggregation, with a heritability of 0.25 (SE = 0.05). Langefeld
et al. [48] report results from diabetes-concordant sib pair
families (662 individuals in 310 families). The heritability of
logACR was 0.42 (SE = 0.12), while that of GFR was 0.75
(0.10). Fox et al. [49] studied logACR in the Framing-
ham families (1055 individuals in 330 families). The
heritability of logACR was 0.20. The best linkage peak
was lod = 2.22 on chromosome 8 (D8S1179). Krolewski
et al. [50] also performed a genome-wide linkage scan
Fig. 4 Effect of ACE insertion-deletion genotype on fasting plasma glucose
Table 3 Additive genetic and environmental correlations and
heritabilities (main diagonal) from mixed model of BP, logACR,
and log transformed fasting plasma glucose (logFPG)
Additive Genetic Non-familial Environmental
sBP dBP logACR logFPG sBP dBP logACR logFPG
sBP 0.26 0.74
dBP 0.74 0.11 0.47 0.88
logACR 0.22 0.81 0.55 0.22 0.21 0.45
logFPG -0.73 -0.15 0.38 0.06 0.24 0.16 0.16 0.94
Table 4 Parameter estimates for fixed effects regression part of
mixed model for logACR, BP and log fasting plasma glucose
Trait Predictor Estimate ASE Wald P-value
logACR Male Sex -0.114 0.0830
Age 0.029 0.0030
Weight -0.0007 0.0009
ACE*D 0.47 0.13 0.0003**
TP53*P 0.20 0.074 0.007**
sBP Male Sex 10.5 1.6
Age 0.52 0.061
Weight -0.0015 0.0017
ACE*D 6.8 2.5 0.006**
TP53*P -0.5 1.4 0.72
dBP Male Sex 7.2 1.5
Age 0.38 0.056
Weight -0.0017 0.0016
ACE*D 8.2 2.2 0.0005**
TP53*P -0.6 1.2 0.62
Log Fasting plasma
glucose
Male Sex 0.031 0.022
Age 0.0029 0.00067
Weight 0.0020 0.00053
ACE*D 0.050 0.026 0.019*
TP53*P 0.0019 0.013 1.0
* highlights a P-value in the range 0.01-0.05
** highlights a P-value <0.01
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of logACR in 63 diabetic families. The heritability of
logACR was significant in both diabetic (h2 = 0.23, P =
0.0007) and nondiabetic (h2 = 0.39, P = 0.0001) family
members, and the difference in genetic variance be-
tween diabetic and nondiabetic relatives was not statis-
tically significant (P = 0.16). There was evidence of
genetic linkage of logACR to regions on chromo-
some 22q (lod = 3.7) and chromosome 7q (lod = 3.1).
In the 59 Caucasian families, an additional locus on
5q (lod = 3.4) also reached significance. Overall, the
point estimates of the heritability for logACR from
these studies are lower than in the present analysis, but
within the 95% confidence interval of our estimate.
More recently, several genome-wide association stud-
ies have also been reported for UACR [51–53], as well as
eGFR and ESRD [54–57]. Böger and colleagues [52] re-
port a coding variant (rs1801239, I2984V) in the cubilin
gene (CUBN) to be significantly associated with UACR.
The second best SNP was rs13177732. For idiopathic
membranous nephropathy, SNPs in PLA2R1 (rs4664308)
and HLA-DQA1 (rs2187668) have been shown to be
important in Caucasians, while multiple loci are risk fac-
tors for IgA nephropathy in Asians. It should be noted
in this context that the dominant pathological findings
in the Aboriginal population tend to glomerulomegaly
followed by sclerosis [58]. The effects of the high pene-
trance African pathogenic alleles of APOL1 (rs60910145,
rs73885319, rs71785313) are restricted to non-diabetic
nephropathies, that is focal segmental glomerulosclero-
sis, hypertensive end-stage renal disease, IgA nephropa-
thy, HIV-related and lupus nephritis, but the high
frequency of these alleles in Africa (37%) is strongly
suspected to be due to Darwinian selection on trypano-
somiasis susceptibility [59], a mechanism that will not
act in this Australian population. Susceptibility to
streptococcal infections may also be a genetic risk factor:
mechanistically, Haapasalo et al [60] suggest interactions
between bacteria and Complement Factor H (CFH)
affect pathogeneticity, and found that a variant in CFH
(rs1061170, CFH*Y402H) was weakly associated with se-
vere streptococcal disease in European patients (specula-
tively, we would also highlight that mutations in CFH5 are
associated with C3 glomerulonephritis in Cypriots [61],
though the mechanism in that condition is unknown). No
information on frequency of any of these variants in
Australian Aboriginal populations is available at present.
Conclusions
In conclusion, we have adduced evidence of a significant
genetic contribution to variation in risk of albuminuria
in this Australian Aboriginal community, of a similar
size to that seen in other populations. We demonstrated
that two risk loci, the ACE insertion-deletion polymor-
phisms and the TP53 codon72 each explain comparable
proportions of this variance, but that the ACE D allele,
at least, does not explain the high rates of renal dysfunc-
tion in this community, given that risk allele frequencies
are lower than in other populations. The effect size of
the ACE D allele was, however, slightly greater than that
seen elsewhere.
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